Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01558336
Other study ID # Schistosmiasis
Secondary ID
Status Completed
Phase Phase 3
First received March 16, 2012
Last updated January 16, 2013
Start date August 2008
Est. completion date September 2012

Study information

Verified date January 2013
Source University of Khartoum
Contact n/a
Is FDA regulated No
Health authority Sudan: Ministry of Health
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the impact of praziquantel for the treatment of Schistosoma haematobium infection among schoolchildren in Al Salamania in Central Sudan.


Description:

A longitudinal study will be conducted to evaluate the impact of praziquantel for the treatment of Schistosoma haematobium infection among schoolchildren in Al Salamania in Central Sudan. A cohort of schoolchildren (6-15 years of age) was investigated before and 1 year after treatment with a single dose of praziquantel 40mg/kg.


Recruitment information / eligibility

Status Completed
Enrollment 520
Est. completion date September 2012
Est. primary completion date August 2012
Accepts healthy volunteers No
Gender Both
Age group 6 Years to 15 Years
Eligibility Inclusion Criteria:

- School children

Exclusion Criteria:

- Taking praziquantel

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
praziquantel
praziquantel 40 mg/kg oral tablets

Locations

Country Name City State
Sudan Al Salamania Al Salamania Nile

Sponsors (2)

Lead Sponsor Collaborator
University of Khartoum Hikma

Country where clinical trial is conducted

Sudan, 

References & Publications (1)

Ahmed AM, El Tash LA, Mohamed EY, Adam I. High levels of Schistosoma mansoni infections among schoolchildren in central Sudan one year after treatment with praziquantel. J Helminthol. 2012 Jun;86(2):228-32. doi: 10.1017/S0022149X11000290. Epub 2011 Jun 8. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary cure rate The reduction of the prevalence and intensity of S.haematobium infection following a single dose of praziquantel40mg/kg one year No
Secondary reduction in the intensity of infection by will a single dose of PZQ significantly reduced intensity of infection of S. haematobium infection 1 year after treatment one year No
See also
  Status Clinical Trial Phase
Completed NCT04115072 - Treatment of Female Genital Schistosomiasis (FGS) With Praziquantel: A Proof-of-Concept Study Phase 2/Phase 3
Not yet recruiting NCT05999825 - Sm-p80 Schistosomiasis Challenge Study Phase 2
Completed NCT00463931 - Using Community-Based Volunteers to Reach Non-Enrolled School Aged Children Through Community-Directed Treatment of Schistosomiasis in School-Aged Children in Rural Northern Ghana N/A
Completed NCT00215267 - The Effect of Praziquantel Treatment on Schistosoma Mansoni Morbidity and re-Infection Along Lake Victoria, Uganda N/A
Completed NCT00276224 - Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia N/A
Completed NCT03845140 - L-PZQ ODT in Schistosoma Infected Children Phase 3
Completed NCT01512277 - Clinical Trial of Bilhvax,a Vaccine Candidate Against Schistosomiasis Phase 1
Active, not recruiting NCT03910972 - Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults Phase 1/Phase 2
Completed NCT05085470 - Repeated Controlled Human Schistosoma Mansoni Infection N/A
Completed NCT02755324 - Single-sex Controlled Human Schistosomiasis Infection: Safety and Dose Finding N/A
Recruiting NCT05868005 - Delivering a Multi-disease Screening Tool to Migrant Populations N/A
Active, not recruiting NCT01869465 - Evaluation of Strategies for Improved Uptake of Preventive Treatment for Intestinal Schistosomiasis N/A
Completed NCT01553552 - Schistosomiasis Effect on Response to Vaccines, Anaemia and Nutritional Status of Children of Northern Senegal N/A
Recruiting NCT04589390 - Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension Phase 2
Completed NCT02868385 - Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST) Phase 3
Recruiting NCT05762393 - A Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Sm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar Phase 1
Not yet recruiting NCT06182176 - Effectiveness and Cost-effectiveness of Integrated Model for Malaria and Helminth Control N/A
Completed NCT05292391 - Safety, Tolerability, and Immunogenicity Study of Sm-p80 + GLA-SE (SchistoShield(R)) Vaccine in Healthy Adults Phase 1
Completed NCT03110757 - A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults Phase 1
Completed NCT01154049 - Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis Phase 1